MDGL compared with KYMR: revenue, margins and what each company keeps, and the suppliers and customers both name

MDGLMadrigal Pharmaceuticals, Inc.

Mkt capRevenueRevenue

KYMRKymera Therapeutics, Inc.

Mkt capRevenueRevenue

Compare

MDGLMadrigal Pharmaceuticals, Inc.

KYMRKymera Therapeutics, Inc.

Price

Mkt cap

Revenue

Revenue flow Supply chain Price Co-movers Event sensitivity Earnings history

Save comparison

Earnings history

News Findings Companies A–Z Pricing Methodology Sources Corrections About Terms

Not investment advice. Not a broker-dealer. Indices shown as ETF proxies. Supply-chain data CC BY 4.0; market data not redistributable.

Listed on One’s Vibe · live-checked · Oct ’26

Desk News Calendar Saved

Earnings history

last 4 reports each · paired by recencyMethod ›

MDGL

1 of 4at or beyond implied

Reportimpliedrealized× implied

Q2 FY26±10.5%▼−9.83%×0.93

Q1 FY26±9.2%▲+7.42%×0.80

Feb 19 '26±6.2%▼−11.11%×1.79

Nov 4 '25±12.9%▲+7.83%×0.60

KYMR

0 of 4at or beyond implied

Reportimpliedrealized× implied

Q3 FY26±18.2%▲+0.07%×0.01

Q2 FY26±10.4%▲+1.04%×0.10

= impliedMDGL realized, solidKYMR realized, hatchedOne scale, both sides: full bar = 19%× = |realized| ÷ impliedSource: market data

Q1 FY26

±10.3%

▼−0.54%

×0.05

Feb 26 '26±11.8%▲+4.80%×0.41

MDGLMadrigal Pharmaceuticals, Inc.

432.96· pre 429.75· delayed

Mkt cap$9.9BRevenue$431MQ3 FY26Revenue$958MFY25

KYMRKymera Therapeutics, Inc.

127.54· pre 127.21· delayed

Pre-marketNov 3 '26delayed

Mkt cap$10.8BRevenue$65MQ2 FY26Revenue$39MFY25

Compare

Pre-marketNov 3 '26delayed

MDGLMadrigal Pharmaceuticals, Inc.

KYMRKymera Therapeutics, Inc.

432.96pre 429.75delayed

Price

127.54pre 127.21delayed

$9.9B

Mkt cap

$10.8B

Q3 FY26$431M

Revenue

$65MQ2 FY26

FY25$958M

Revenue

$39MFY25

MDGL432.96vsKYMR127.54Pre-marketNov 3 '26delayed